Illumina, Inc. (NASDAQ:ILMN) SVP Mostafa Ronaghi Sells 10,000 Shares

Illumina, Inc. (NASDAQ:ILMN) SVP Mostafa Ronaghi sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, July 15th. The stock was sold at an average price of $302.04, for a total transaction of $3,020,400.00. Following the sale, the senior vice president now owns 86,776 shares of the company’s stock, valued at approximately $26,209,823.04. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Mostafa Ronaghi also recently made the following trade(s):

  • On Monday, June 17th, Mostafa Ronaghi sold 10,000 shares of Illumina stock. The stock was sold at an average price of $349.28, for a total transaction of $3,492,800.00.
  • On Wednesday, May 15th, Mostafa Ronaghi sold 10,000 shares of Illumina stock. The stock was sold at an average price of $305.49, for a total transaction of $3,054,900.00.

ILMN stock opened at $293.20 on Friday. The firm has a fifty day simple moving average of $342.44. Illumina, Inc. has a 12 month low of $268.62 and a 12 month high of $380.76. The stock has a market cap of $43.89 billion, a P/E ratio of 51.26, a price-to-earnings-growth ratio of 2.60 and a beta of 1.15. The company has a debt-to-equity ratio of 0.27, a quick ratio of 3.33 and a current ratio of 3.66.

Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Thursday, April 25th. The life sciences company reported $1.60 EPS for the quarter, beating the consensus estimate of $1.34 by $0.26. Illumina had a net margin of 25.06% and a return on equity of 23.49%. The firm had revenue of $846.00 million during the quarter, compared to the consensus estimate of $838.70 million. During the same quarter in the prior year, the firm earned $1.45 EPS. Illumina’s revenue for the quarter was up 8.2% on a year-over-year basis. As a group, research analysts anticipate that Illumina, Inc. will post 6.34 EPS for the current year.

Several analysts have recently weighed in on the stock. Cowen boosted their price objective on shares of Solaredge Technologies from $65.00 to $74.00 and gave the stock an “outperform” rating in a research report on Friday, July 12th. Bank of America set a $80.00 price objective on shares of Colgate-Palmolive and gave the stock a “buy” rating in a research report on Friday, July 12th. Argus boosted their price objective on shares of Canadian Pacific Railway to $265.00 and gave the stock a “buy” rating in a research report on Thursday. ValuEngine downgraded shares of Vereit from a “buy” rating to a “hold” rating in a research report on Friday. Finally, BidaskClub downgraded shares of Weyco Group from a “sell” rating to a “strong sell” rating in a research report on Saturday, July 13th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and thirteen have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $338.69.

A number of hedge funds have recently added to or reduced their stakes in ILMN. Norges Bank purchased a new position in Illumina during the 4th quarter worth $514,627,000. Thoroughbred Financial Services LLC raised its position in Illumina by 38,516.8% during the 2nd quarter. Thoroughbred Financial Services LLC now owns 875,828 shares of the life sciences company’s stock worth $87,583,000 after buying an additional 873,560 shares during the last quarter. American Century Companies Inc. raised its position in Illumina by 107.1% during the 1st quarter. American Century Companies Inc. now owns 815,875 shares of the life sciences company’s stock worth $253,484,000 after buying an additional 421,953 shares during the last quarter. MERIAN GLOBAL INVESTORS UK Ltd raised its position in Illumina by 841.1% during the 1st quarter. MERIAN GLOBAL INVESTORS UK Ltd now owns 269,170 shares of the life sciences company’s stock worth $83,628,000 after buying an additional 240,569 shares during the last quarter. Finally, Bessemer Group Inc. raised its position in Illumina by 8,816.3% during the 2nd quarter. Bessemer Group Inc. now owns 214,525 shares of the life sciences company’s stock worth $78,978,000 after buying an additional 212,119 shares during the last quarter. Hedge funds and other institutional investors own 89.81% of the company’s stock.

About Illumina

Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array.

See Also: Moving Average Convergence Divergence (MACD)

Insider Buying and Selling by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.